Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The von Willebrand factor.

F Rodeghiero1, G Castaman

  • 1Divisione di Ematologia, Ospedale San Bortolo, Vicenza.

La Ricerca in Clinica E in Laboratorio
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Quantitative measurement of von Willebrand factor (vWf) involves ristocetin cofactor activity (RiCof) and vWf antigen (vWf:Ag) assays. RiCof is preferred for diagnosing von Willebrand disease (vWd), detecting at least 50% of carriers, while vWf:Ag shows lower sensitivity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2020
Same author

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Thrombopoietin receptor agonists in hereditary thrombocytopenias.

Journal of thrombosis and haemostasis : JTH·2018
Same author

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Increase of plasma tissue-plasminogen activator antigen levels after induced abortion.

La Ricerca in clinica e in laboratorio·1991
Same journal

Role of prostaglandin E2 on defective interferon-gamma production during type B acute viral hepatitis.

La Ricerca in clinica e in laboratorio·1991
Same journal

The use of recombinant factor VIII in the management of hemophilia.

La Ricerca in clinica e in laboratorio·1991
Same journal

The functioning liver mass.

La Ricerca in clinica e in laboratorio·1991
Same journal

Liver system. V. Activation-extinction line of cyclic hepatocyte activities.

La Ricerca in clinica e in laboratorio·1991
Same journal

Liver system. IV. More on the liver micro-unit: physics and geometry of its action.

La Ricerca in clinica e in laboratorio·1991
See all related articles

Area of Science:

  • Hematology
  • Clinical Chemistry
  • Molecular Diagnostics

Background:

  • Von Willebrand factor (vWf) is crucial for platelet adhesion and Factor VIII stabilization.
  • Quantitative vWf measurement is essential for diagnosing von Willebrand disease (vWd).
  • Two primary methods exist: ristocetin cofactor activity (RiCof) and vWf antigen (vWf:Ag).

Purpose of the Study:

  • To compare the diagnostic utility of RiCof and vWf:Ag assays for vWd.
  • To evaluate the precision and clinical applicability of these quantitative methods.
  • To highlight the need for standardized normal ranges and interlaboratory comparability.

Main Methods:

  • Ristocetin cofactor activity (RiCof) assay measuring vWf-platelet interaction.
  • Immunological quantitation of vWf antigen (vWf:Ag) using immunoassays (e.g., ELISA).

Related Experiment Videos

  • Interassay variability assessment using control plasmas and comparison with international standards.

    • Main Results:

    • RiCof assay detects at least 50% of vWd carriers, showing higher sensitivity than vWf:Ag (64% in this study).
    • Discrepancies between RiCof and vWf:Ag are common in type II vWd.
    • Both assays demonstrate sufficient precision (variability < 8.5%) for clinical use, but require specific normal ranges for different populations.

    Conclusions:

    • RiCof assay, alongside family history, is the preferred method for diagnosing congenital and acquired vWd.
    • vWf:Ag assay is less sensitive for detecting vWd.
    • Standardization of assays, including definition of population-specific normal ranges and collaborative studies, is crucial for reliable interlaboratory measurements.